NRSN is trading 3% up at $0.78 as investors position ahead of its June 30, 2026, Q1 earnings report and react to positive clinical and financing updates.
- The company reported encouraging biomarker data in Alzheimer’s disease and received new patent protection for its lead candidate, PrimeC.
- Sentiment is further bolstered by recently secured fresh funding at a premium, supporting the ongoing development of its ALS and Alzheimer’s pipeline.